Lexaria Bioscience (LEXX) Cost of Revenue (2017 - 2024)
Lexaria Bioscience (LEXX) posted Cost of Revenue of $2720.0 for Q4 2024, down 43.59% sequentially from $4822.0 in Q4 2023, and down 43.59% YoY from $4822.0 in Q4 2023.
Lexaria Bioscience (LEXX) Cost of Revenue (2017 - 2024) Analysis & Trends
Lexaria Bioscience has reported Cost of Revenue for 8 years, with the latest figure at $2720.0 in Q4 2024.
- Quarterly Cost of Revenue fell 43.59% year-over-year to $2720.0 in Q4 2024, while the trailing twelve-month figure through Aug 2025 was $2720.0 (down 43.59% YoY) and the FY2025 annual result came in at $2720.0, down 43.59% from the prior year.
- Cost of Revenue retreated to $2720.0 in Q4 2024 per LEXX's latest filing, from $4822.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $64478.0 in Q4 2020 and troughed at $2720.0 in Q4 2024.
- A 5-year average of $23609.6 and a median of $17215.0 in 2022 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2020 and 2021: Cost of Revenue soared 2060.07% in 2020, then tumbled 91.36% in 2021.
- Over 5 years, Cost of Revenue stood at $64478.0 in 2020, then sank by 91.36% to $5570.0 in 2021, then soared by 183.57% to $15795.0 in 2022, then sank by 69.47% to $4822.0 in 2023, then slumped by 43.59% to $2720.0 in 2024.
- According to Business Quant data, Cost of Revenue over the past three periods registered $2720.0, $4822.0, and $12747.0 for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2024 | 2,720.00 |
| Nov 30, 2024 | 2,720.00 |
| Nov 30, 2023 | 4,822.00 |
| Nov 30, 2023 | 4,822.00 |
| May 31, 2023 | 12,747.00 |
| May 31, 2023 | 12,747.00 |
| Feb 28, 2023 | 2,958.00 |
| Feb 28, 2023 | 2,958.00 |
| Nov 30, 2022 | 15,795.00 |
| Nov 30, 2022 | 15,795.00 |
| Aug 31, 2022 | 41,249.00 |
| Aug 31, 2022 | 41,249.00 |
| May 31, 2022 | 18,635.00 |
| May 31, 2022 | 18,635.00 |
| Feb 28, 2022 | 6,387.00 |
| Feb 28, 2022 | 6,387.00 |
| Nov 30, 2021 | 5,570.00 |
| Nov 30, 2021 | 5,570.00 |
| Aug 31, 2021 | 20,309.00 |
| Aug 31, 2021 | 20,309.00 |